Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2025
0mins
Source: Yahoo Finance
AGM Outcomes: Pharming Group N.V. held its Annual General Meeting where all proposals were approved, including the appointment of Dr. Elaine Sullivan to the Board and the reelection of Mrs. Jabine van der Meijs and Mr. Leonard Kruimer as Non-Executive Directors.
Board Changes and Auditor Reappointment: After six years, Mrs. Deborah Jorn and Mr. Steven Baert did not seek reelection, while Deloitte Accountants B.V. was reappointed as the external auditor for 2025, alongside renewed authorizations for share issuance and repurchase.
Analyst Views on PHAR
Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 19.930
Low
37.00
Averages
39.50
High
42.00
Current: 19.930
Low
37.00
Averages
39.50
High
42.00
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
